Overview: Bence Jones Protein TestIntroduction: The Bence Jones Protein Test detects proteins in urine linked to multiple myeloma, causing bone pain or kidney issues. Following 2023 IMWG guidelines, it uses electrophoresis for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in clinical pathology for patients with suspected multiple myeloma.
Other Names: Bence Jones Protein Assay, Myeloma Protein Test.
FDA Status: Laboratory-developed test (LDT), meeting clinical pathology standards for diagnostic accuracy.
Historical Milestone: Bence Jones protein testing began in the 1840s with urine analysis. Electrophoresis methods emerged in the 1960s, and by the 2000s, high-resolution techniques improved myeloma detection.
Purpose: Diagnoses multiple myeloma, guides treatment, and monitors disease activity in patients with bone pain or kidney issues.
Test Parameters: 1. Bence Jones Protein
Pretest Condition: No fasting required. Collect urine at any time. Report symptoms like bone pain or kidney dysfunction, and list medications like chemotherapy agents.
Specimen: 5-20 mL urine (sterile container). Transport in a biohazard bag within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document bone pain, kidney issues, or family history of multiple myeloma. Include current medications, especially chemotherapy or bisphosphonates.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for chemotherapy or bone marrow biopsy.
Procedural Considerations: Uses electrophoresis to detect Bence Jones proteins. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Improper storage or delayed transport can degrade proteins. Low protein levels may cause false negatives.
Clinical Significance: Positive results confirm multiple myeloma, prompting chemotherapy or stem cell transplant. Negative results may require serum protein electrophoresis.
Specialist Consultation: Consult a hematologist for result interpretation. An oncologist referral is advised for treatment planning.
Additional Supporting Tests: Serum protein electrophoresis, bone marrow biopsy, or beta-2-microglobulin test to confirm multiple myeloma or assess disease extent.
Test Limitations: False negatives may occur with low-level disease. Results require clinical correlation with imaging or biopsy.
References: IMWG Myeloma Guidelines, 2023; Blood, Rajkumar SV, 2022.
